Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
Characterization of [18F]SMBT-1 binding substrates in Alzheimer's disease and related disorders: A postmortem biochemical and immunohistochemical study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Abrahamson Eric E, Kofler Julia K, Lopez Oscar L, Cohen Anne D, Gogola Alexandra, Aizenstein Howard J, Karikari Thomas K, Mufson Elliott J, Villemagne Victor L, Ikonomovic Milos D
Аннотация
INTRODUCTION: Neuroimaging studies report associations of amyloid beta (Aβ) positron emission tomography (PET) with [18F](S)-(2-methylpyrid-5-yl)-6-[(3-fluoro-2-hydroxy)propoxy]quinoline ([18F]SMBT-1), a novel reactive astrogliosis surrogate radiotracer with high affinity for monoamine oxidase B (MAO-B) in Alzheimer's disease (AD). Postmortem association of [18F]SMBT-1 binding with pathology of AD and non-AD tauopathies is undefined.
METHODS: [18F]SMBT-1 binding, [3H]Pittsburgh compound B ([3H]PiB) binding, and MAO-B activity assays in brain homogenates, with [18F]SMBT-1 autoradiography and MAO-B immunoreactivity in relation to glial fibrillary acidic protein (GFAP), major histocompatibility complex II (MHC-II), Aβ, phosphorylated tau, cyano-Pittsburgh compound B (cyano-PiB), and X-34 on brain sections from AD, non-AD tauopathies, and nondemented controls.
RESULTS: [18F]SMBT-1 binding correlated with MAO-B activity and [3H]PiB binding, with highest levels in AD. [18F]SMBT-1 autoradiography corresponded to MAO-B/GFAP-immunoreactive astrocytes associated with Aβ deposits in plaques and vasculature, more closely than to tau pathology. [18F]SMBT-1 binding and MAO-B activity in non-AD tauopathies partially overlapped controls and AD, with MAO-B/GFAP-immunoreactive astrocytes in areas with tau pathology.
DISCUSSION: [18F]SMBT-1 is a promising biomarker of MAO-B reactive astrocytes in AD and non-AD tauopathies.
METHODS: [18F]SMBT-1 binding, [3H]Pittsburgh compound B ([3H]PiB) binding, and MAO-B activity assays in brain homogenates, with [18F]SMBT-1 autoradiography and MAO-B immunoreactivity in relation to glial fibrillary acidic protein (GFAP), major histocompatibility complex II (MHC-II), Aβ, phosphorylated tau, cyano-Pittsburgh compound B (cyano-PiB), and X-34 on brain sections from AD, non-AD tauopathies, and nondemented controls.
RESULTS: [18F]SMBT-1 binding correlated with MAO-B activity and [3H]PiB binding, with highest levels in AD. [18F]SMBT-1 autoradiography corresponded to MAO-B/GFAP-immunoreactive astrocytes associated with Aβ deposits in plaques and vasculature, more closely than to tau pathology. [18F]SMBT-1 binding and MAO-B activity in non-AD tauopathies partially overlapped controls and AD, with MAO-B/GFAP-immunoreactive astrocytes in areas with tau pathology.
DISCUSSION: [18F]SMBT-1 is a promising biomarker of MAO-B reactive astrocytes in AD and non-AD tauopathies.